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Abstract Based on recent information about the anti-substrate
binding mode of the propeptide portion of procathepsin B and the
well established substrate-like binding of epoxysuccinyl-dipeptide
carboxylates to the SP subsites of cathepsin B a new endo-trans-
epoxysuccinyl peptide was synthesized that contains the dipeptide
moiety Leu-Pro-OH for the P1P^P2P substrate positions and the
tripeptide moiety Leu-Gly-Gly-OMe (sequence portion 46^48 of
the propeptide) for the P2^P4 positions in anti-substrate
orientation. With an unequivocal (2S,3S) configuration this
new trans-epoxysuccinyl peptide derivative was found to inhibit
cathepsin B with an apparent second-order rate constant of
1 520 000 M31 s31 which represents so far the most potent
inhibitor among E-64-derived compounds. Conversely, the
(2R,3R) diastereomer exhibited a significantly lower inhibition
potency. This observation fully agrees with our previous findings
that inhibitor/enzyme interactions at the S subsites are favored
by the (2S,3S) and reverse interactions at the SP subsites by the
(2R,3R) configuration of the trans-epoxysuccinyl moiety.
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1. Introduction
Lysosomal cysteine proteases are known to play important
roles in intracellular protein degradation [1] and antigen proc-
essing [2], but have also been implicated in various patholog-
ical processes like bone resorption [3], tumor invasion and
metastasis [4], cartilage degradation in arthritis [5] and mus-
cular dystrophy [6]. This major role in pathological conditions
makes them promising targets for inhibitor development.
Among these lysosomal enzymes cathepsin B represents a
major component that exhibits both endopeptidase and exo-
peptidase activities. The design of highly selective inhibitors of
the cathepsin class of cysteine proteases was found to be dif-
¢cult because of their broad substrate speci¢city [7]. Never-
theless, some success was obtained with synthetic analogs of
the natural product (2S,3S)-trans-epoxysuccinyl-L-leucyl-ag-
matine (E-64), which is a very powerful irreversible inhibitor
of cysteine proteases although of limited selectivity [8,9].
Valuable information on the mode of binding of these
trans-epoxysuccinyl-based inhibitors is meanwhile available
from the X-ray structures of their adducts to actinidin [10],
papain [11^13] and cathepsin B [14,15], thus enabling a struc-
ture-based design of new inhibitors of enhanced a⁄nity and
selectivity. In this context we have recently synthesized a series
of trans-epoxysuccinyl peptide derivatives both in the (2R,3R)
and (2S,3S) con¢guration in order to analyze the role of the
stereochemistry of this residue in dictating inhibitory potency
and selectivity for cysteine proteases [16]. We con¢rmed that
binding of E-64-type trans-epoxysuccinyl-based inhibitors to
the S subsites of the enzymes is highly favored by the (2S,3S)
con¢guration, whereas CA030-type inhibitors that exploit in-
teractions with the occluding loop of cathepsin B for prefer-
ential binding to the SP subsite [14,15] are stronger inhibitors
in the (2R,3R) con¢guration than the related (2S,3S) diaster-
eomers. Consequently, the design of bis-peptidyl derivatives of
the trans-epoxysuccinic acid to possibly increase the selectivity
of this class of inhibitors is hampered by the non-additivity of
the con¢gurational requirements for optimal interaction with
both the S and SP subsites [16].
The cysteine proteases are produced in vivo as inactive
precursors that contain an additional N-terminal propeptide
extension. This propeptide has been shown to act as a potent
and highly selective inhibitor of the mature enzymes [17,18].
Recently the X-ray structures of rat [19] and human proca-
thepsin B [20] have been reported which revealed binding of
the propeptide segment in anti-substrate mode to the active-
site cleft of the enzyme. A superposition of E-64, as structured
in the actinidin [10] and papain [11,12] adducts, to the pro-
peptide segment bound to the substrate binding site of the
enzyme revealed a shift of the E-64 relative to the propeptide
within the binding site by approximately one bond length, a
fact which results from the four-carbon backbone of the suc-
cinyl moiety vs. the three-atom backbone of an amino acid
residue [19]. While in E-64 the leucine side chain occupies the
S2 subsite near Leu-46 of the propeptide, the related P2 res-
idue of the propeptide, i.e. Thr-44, is shifted towards the edge
of the S2 pocket in the direction of the active site. Moreover,
it is well established that the peptidyl dipeptidase activity of
cathepsin B is dependent on the presence of the occluding
loop with the two His residues 110 and 111 accepting the
negative charge of the P2P carboxylate [14,15]. Therefore, to
mimic the reverse propeptide binding to the S subsites as well
as the normal substrate binding to the SP subsites the endo-
trans-epoxysuccinyl peptide, shown in Fig. 1, was designed
where (i) the dipeptide moiety Leu-Pro-OH was selected for
the P1P^P2 substrate positions in agreement with previous
positive experiences with related trans-epoxysuccinyl deriva-
tives [8,9,16] and (ii) the tripeptide moiety Leu-Gly-Gly-
OMe (sequence portion 46^48 of the propeptide) was selected
for the P2^P4 positions in anti-substrate orientation.
2. Materials and methods
2.1. Materials
Solvents and reagents for the synthesis were of the highest quality
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commercially available. Papain (EC 3.4.22.2) from Boehringer (Mann-
heim) was rechromatographed on S-Sepharose as described [21].
Human cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.15)
were purchased from Calbiochem (Bad Soden/Taunus), Z-Phe-Arg-
NH-Mec from Bachem (Heidelberg), E-64, trans-epoxysuccinyl-L-leu-
cylamido-(4-guanidino)butane (2a) and all other chemicals from Sig-
ma. NMR spectra were recorded on a Bruker AMX500 spectrometer
and FAB-MS spectra on a Finnigan MAT 900. TLC was carried out
on silica gel 60 plates (Merck AG, Darmstadt) and analytical HPLC
with Waters equipment on Nucleosil 300/C18 (Machery and Nagel,
Duºren) using a linear gradient of acetonitrile/2% H3PO4 from 95:5 to
20:80 in 30 min.
2.2. Synthesis of the trans-epoxysuccinyl-peptides
The trans-epoxysuccinyl (tEps) peptides HO-(2R,3R)-tEps-Leu-
Agm (2b), EtO-(2R,3R)-tEps-Leu-Pro-OH (3a) and EtO-(2S,3S)-
tEps-Leu-Pro-OH (3b) were synthesized as described previously [16].
2.2.1. MeO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (1a). HO-
(2S,3S)-tEps-Leu-Pro-OtBu [16] was reacted overnight at room tem-
perature with H-Leu-Gly-Gly-OMe (1.2-fold excess) in chloroform by
ECD/HOBt. The solvent was evaporated and the residue was washed
in ethyl acetate successively with 5% KHSO4, 5% NaHCO3 and water.
The organic layer was dried over MgSO4 and evaporated to dryness;
yield: 95%; homogeneous on TLC (CHCl3/MeOH, 4:1; Rf 0.75) and
HPLC (tR 21.0 min); 1H-NMR (DMSO-d6) spectrum: consistent with
the assigned structure.
The product was deprotected by exposure to 20% tri£uoroacetic
acid in CHCl3 for 24 h at room temperature. The solvent was evapo-
rated and the residue precipitated from ethyl acetate with petroleum
ether; yield: 83%; homogeneous on HPLC (tR 16.5 min); 1H-NMR
(DMSO-d6) N= 0.82^0.95 (m, 12H, 2UN1CH3 Leu, 2UN2CH3 Leu),
1.40^1.70, 1.84, 1.93, 2.15 (4 m, 10H, 2ULCH2 Leu, 2UQCH Leu,
LCH2 Pro, QCH2 Pro), 3.63 (s, 3H, OCH3), 3.48^3.79 (br. m, 6H,
N1CH2 Pro, N2CH2 Pro, 2UCH tEps, KCH2 Gly), 3.86 (m, 2H,
(KCH2 Gly), 4.26 (m, 1H, KCH Pro), 4.38 (m, 1H, KCH Leu), 4.62
(m, 1H, KCH Leu), 8.18 (m, 1H, NH Gly), 8.36 (m, 1H, NH Gly),
8.55 (d, 1H, J = 8.1 Hz, NH Leu), 8.71 (d, 1H, J = 8.1 Hz, NH Leu);
FAB-MS: m/z 584.2 [M+H] ; calcd. for C26H41N5O10 : 583.
2.2.2. MeO-Gly-Gly-Leu-(2R,3R)-tEps-Leu-Pro-OH (1b). The ti-
tle compound was prepared from HO-(2R,3R)-tEps-Leu-Pro-OtBu
and H-Leu-Gly-Gly-OMe as described for 1a ; yield: 90% over the
two steps; homogeneous on HPLC (tR 16.5 min); 1H-NMR
(DMSO-d6) N= 0.81^0.94 (m, 12H, 2UN1CH3 Leu, 2UN2CH3 Leu),
1.40^1.70, 1.84, 1.93, 2.16 (4 m, 10H, 2ULCH2 Leu, 2UQCH Leu,
LCH2 Pro, QCH2 Pro), 3.51 (m, 1H, N2CH2 Pro), 3.63 (m, 5H, 2UCH
tEps, OCH3) 3.71 (m, 1H, N1CH2 Pro), 3.73 (d, 2H, J = 5.8 Hz, KCH2
Gly), 3.85 (m, 2H, KCH2 Gly), 4.25 (m, 1H, KCH Pro), 4.33 (m, 1H,
KCH Leu), 4.57 (m, 1H, KCH Leu), 8.18 (m, 1H, NH Gly), 8.29 (m,
1H, NH Gly), 8.58 (d, 1H, J = 8.1 Hz, NH Leu), 8.66 (d, 1H, J = 8.0
Hz, NH Leu); FAB-MS: m/z 584.2 [M+H] ; calcd. for
C26H41N5O10 : 583.
2.3. Enzyme inhibition assays
Continuous £uorometric inhibition assays were performed and eval-
uated as described in detail elsewhere [21,22]. Inhibition of papain (10
pM), cathepsin B (27 pM) and cathepsin L (5 pM) were assayed at
30‡C with the substrate Z-Phe-Arg-NH-Mec (for cathepsin B 10 WM,
Km = 220 WM; for papain 10 WM, Km = 52 WM; for cathepsin L 4 WM,
Km = 2.9 WM) in 1.2 ml of 0.25 M sodium acetate bu¡er pH 5.5,
containing 2 mM EDTA, 0.015% Brij-35, 1 mM dithiothreitol (added
fresh), 1% DMSO (from added substrate solution). The inhibitors
were dissolved in DMSO or water (10 mM), diluted in bu¡er or
DMSO and added in 1^10 Wl to the preactivated enzymes after a
constant substrate release was observed. The ¢nal inhibitor concen-
trations in the assay were in the range of 0.6 nM to 30 nM in order to
achieve almost complete inhibition within 15^90 min.
The apparent pseudo-¢rst-order rate constant kobs was obtained
from the pre-steady-state phase of the progress curve as described
by Morrison [23] and Knight [24] by non-linear regression analysis
of the collected data using the commercial program FigP (Biosoft,
Cambridge). The apparent second-order rate constants k2/Ki were
then calculated as k2/Ki = kobs/[I] when kobs increased linearly with
increasing inhibitor concentration ([I]IKi). Substrate depletion was
6 5% within the duration of the experiments; a correction was made
for competition of the inhibitors with the substrate.
3. Results and discussion
Using diethyl L-(+)- and D-(3)-tartrate as starting com-
pounds for the synthesis of the (2R,3R)- and (2S,3S)-trans-
epoxysuccinic acid intermediates [16,25] the two epoxysuccinyl
peptides 1a and 1b were obtained as homogeneous com-
pounds and well de¢ned in the con¢guration at the C2 and
C3 atoms of the trans-epoxysuccinyl group as the (2S,3S) and
(2R,3R) diastereomer, respectively. The inhibition of papain,
cathepsin B and cathepsin L by these two new compounds
was compared to the inhibitory potencies of (2S,3S)-E-64
(natural compound) (2a) and (2R,3R)-E-64 (2b), and of
(2S,3S)-EtO-tEps-Leu-Pro-OH (3a) and (2R,3R)-EtO-tEps-
Leu-Pro-OH (3b), determined previously [16].
As shown in Table 1, extension of the inhibitors 3a,b which
most probably bind to the enzymes in the CA030 mode, i.e. to
the SP subsites [14], with the propeptide portion Leu-Gly-Gly-
OMe, expected to bind to the S subsites, leads to strongly
di¡erentiated e¡ects depending upon the con¢guration of
the trans-epoxysuccinyl moiety. Compound 1a with the
(2S,3S) con¢guration was found to be the most potent epoxy-
succinyl-based inhibitor of cathepsin B known so far, whereas
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Fig. 1. Schematic presentation of the proposed binding mode of 1a ;
S3 symbolizes the side chain thiolate of Cys-29, and the arrow indi-
cates the oxirane carbon where the nucleophilic attack of Cys-29
should occur according to Yamamoto et al. [15].
Table 1











MeO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH (1a) 14 800 þ 1 077 1 520 000 þ 88 800 1 204 þ 29 103 1 262
MeO-Gly-Gly-Leu-(2R,3R)-tEps-Leu-Pro-OH (1b) 870 þ 65 214 600 þ 11 980 269 þ 23 247 798
HO-(2S,3S)-tEps-Leu-Agm, E-64 (2a) 869 000 þ 23 500 81 400 þ 2 760 43 800 þ 4 390 0.09 1.9
HO-(2R,3R)-tEps-Leu-Agm (2b) 86 000 þ 3 260 1 170 þ 40 4 930 þ 183 0.01 0.2
EtO-(2S,3S)-tEps-Leu-Pro-OH (3a) 6 130 þ 55 44 400 þ 1 690 170 þ 17 7.2 260
EtO-(2R,3R)-tEps-Leu-Pro-OH (3b) 56 567 000 þ 21 500 26 10 100 21 800
k2/Ki for compounds 1a and 1b were determined at pH 5.5 in 250 mM sodium acetate bu¡er þ S.E.M. from 5^10 experiments and are corrected for
substrate competition. The inhibitory potencies of compounds 2a, 2b, 3a and 3b reported previously [16] are listed for comparison.
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the related (2R,3R) diastereomer 1b exhibited a signi¢cantly
lower inhibitory potency than the SP sites binding 3b. This
would strongly support our previous observation that inhib-
itor-enzyme interactions at the S subsites are favored by the
(2S,3S) and reverse interactions at the SP subsites by the
(2R,3R) con¢guration [16]. Thus, in the case of both inhibi-
tors 1a and 1b the binding contributions to the S subsites
apparently prevail over those to the SP subsites. This is further
supported by the lower selectivity of 1a and 1b for cathepsin B
vs. cathepsin L than 3b. However, only X-ray analysis of the
complexes of cathepsin B with the two new diastereomers
could con¢rm whether a loss or weaker interaction of the
dipeptide carboxylate moiety with the occluding loop, the
characteristic structural feature of cathepsin B, is responsible
for the observed lower selectivity.
Because of the extremely high inhibitory potency of the new
trans-epoxysuccinyl compound 1a with its k2/Ki value of
1 520 000 M31 s31 and selectivity ratio of 1260 vs. cathepsin
it represents a promising tool for selective inhibition of ca-
thepsin B both in vitro and in vivo.
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